Navigation Links
Cytokinetics Reports Additional Clinical Trials Data for Ispinesib

Results Reported From Three NCI-Sponsored Clinical Trials

SOUTH SAN FRANCISCO, CA June 28, 2007 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced results from the analyses of three Phase II clinical trials of ispinesib administered as monotherapy, one in patients with hepatocellular cancer, one in patients with melanoma, and one in patients with hormone-refractory prostate cancer. Ispinesib is a novel small molecule inhibitor of kinesin spindle protein (KSP), a mitotic kinesin essential for proper cell division. Ispinesib has arisen from a broad strategic collaboration between Cytokinetics and GlaxoSmithKline (GSK) to discover, develop and commercialize novel small molecule therapeutics targeting human mitotic kinesins for applications in the treatment of cancer and other diseases. All three clinical trials were sponsored by the National Cancer Institute (NCI).

A Phase II clinical trial designed to evaluate the safety and efficacy of ispinesib in the treatment of patients with locally advanced, recurrent or metastatic hepatocellular cancer was recently completed. In Stage 1 of this two-stage clinical trial, 15 patients received ispinesib as monotherapy at 18 mg/m2 as a 1-hour intravenous infusion every 21 days. The trial s primary endpoint was objective response as determined using the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. This trial was designed to require at least 1 confirmed partial or complete response out of 15 evaluable patients in Stage 1 in order to proceed to Stage 2. The best overall response was stable disease seen in 7 of the 15 patients treated. In this clinical trial, ispinesib did not satisfy the criteria for advancement to the second stage and therefore recruitment to Stage 2 was not opened. The toxicity profile was consistent with other previously reported Phase II clinical trials of ispinesib. A manuscript is being prepared.

A Phase
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cytokinetics Announces Non-clinical Data to be Presented at the 2007 AACR Annual Meeting
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:4/24/2015)... , Apr. 24, 2015 Research ... has announced the addition of the ... Pipette tips/ Pumps/Microplate/Reagent Reservoir/Valve/Tubing/Wash Station) & End ... - Global Forecast to 2020" report ... laboratory accessories market is expected to reach ...
(Date:4/24/2015)... The National Institute of Allergy and ... of Health [NIH])  provided grants totaling more than ... development of diagnostic tests for antibiotic-resistant bacteria . ... health facilities , the NIAID and other government ... effective tests using alternative methods to traditional culturing.   ...
(Date:4/24/2015)... , April 24, 2015 /CNW/ - T-Bird Pharma ... focused on developing premium quality medical marijuana products and ... Marihuana for Medical Purposes Regulations ( Canada ... with certain of its shareholders, has closed the transaction ... ("Medna").  Medna has acquired (the "Escrow Transfer") a total ...
Breaking Medicine Technology:Global Lab Accessories Market Report 2015-2020 - Label Printer/ Pipette tips/ Pumps/Microplate/Reagent Reservoir/Valve/Tubing/Wash Station 2Global Lab Accessories Market Report 2015-2020 - Label Printer/ Pipette tips/ Pumps/Microplate/Reagent Reservoir/Valve/Tubing/Wash Station 3Kalorama: NIAID Rewards HAI Innovators with Grants 2Kalorama: NIAID Rewards HAI Innovators with Grants 3Kalorama: NIAID Rewards HAI Innovators with Grants 4T-Bird Pharma Inc. Announces Closing of Transaction with Medna Biosciences 2T-Bird Pharma Inc. Announces Closing of Transaction with Medna Biosciences 3
... Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announces ... bioavailable, highly selective, class I histone deacetylase (HDAC) inhibitor, ... being presented as oral poster discussions at the San ... in San Antonio Texas. The following ...
... AUSTIN, Texas, Dec. 10, 2010 Hanger Orthopedic Group, Inc. ... the previously announced public offering of 2,000,000 shares of its ... public offering price of $20.00 per share.  The transaction is ... were a portion of the currently outstanding shares issued to ...
Cached Medicine Technology:Syndax Pharmaceuticals' Entinostat in Combination Shows Activity in Breast Cancer 2Syndax Pharmaceuticals' Entinostat in Combination Shows Activity in Breast Cancer 3Syndax Pharmaceuticals' Entinostat in Combination Shows Activity in Breast Cancer 4Hanger Orthopedic Group, Inc. Announces Pricing of Underwritten Public Offering by Shareholder 2Hanger Orthopedic Group, Inc. Announces Pricing of Underwritten Public Offering by Shareholder 3
(Date:4/24/2015)... (PRWEB) April 24, 2015 National ... informed and legal access to medical cannabis, is taking ... properly supported when advising patients. , NAC is the ... Program. With a $250,000 grant, NAC will be providing ... , "Our goal is to help Canadians gain safe ...
(Date:4/24/2015)... Telematics Berlin is the foremost Automotive Data ... 2 suppliers, content providers, associations and government bodies. From ... chain, see them converge in Berlin. This year’s start-up ... those companies currently at the forefront of Europe’s Silicon ... customer centric products, ParkTAG are one of the first ...
(Date:4/24/2015)... New York (PRWEB) April 24, 2015 ... partnered with Allergy and Asthma Network (The Network), a ... PURE Solutions will provide news, tips and information for ... The Network’s newly redesigned website. , The goal for ... awareness about the travel needs of people with asthma ...
(Date:4/24/2015)... 2015 ProTube Outro is a set of ... editors. ProTube Outro allows editors to easily manipulate the ... zones. Position, scale, and rotate pictures/videos, logos, social media ... uses simple borders and shadows for a minimalistic and versatile ... ProTube Outro comes packed with over 30 customizable outro screen ...
(Date:4/23/2015)... 23, 2015 On April 8th, 2015, ... Movie Awards” EcoLuxe Lounge at the famous Avalon Hollywood. ... product placement in TV and film, the EcoLuxe Lounge ... at several awards ceremonies and festivals throughout the year, ... sound and socially conscious products and services together for ...
Breaking Medicine News(10 mins):Health News:National Access Cannabis Gives 300 Canadian Healthcare Professionals Access to Medical Cannabis Certificate Program 2Health News:Telematics Berlin 2015’s inaugural European Automotive Start-Up Competition 2Health News:Telematics Berlin 2015’s inaugural European Automotive Start-Up Competition 3Health News:PURE Solutions Partners with Allergy and Asthma Network to Provide Allergy Travel Tips 2Health News:Pixel Film Studios, FCPX Plugin Developer Announced the Release of Protube Outro, Outro Screen Templates for Final Cut Pro X 2Health News:Choices Recovery South Bend Talks With Neal Cohen About Long-Term Sobriety 2
... ... ... ... TULSA, Okla. , Feb. 19 U.S. Attorney Thomas Scott ...
... in multinational communities, researchers say , FRIDAY, Feb. 19 (HealthDay ... taught in the accent of the listener, a new study ... adults in the "original" accent of the new language. But ... this method isn,t necessarily the best or quickest way to ...
... The American Association for Dental Research (AADR) is ... Harkin will be recognized at the AADR/Research!America Advocacy Day, ... is being recognized for his commitment to the National ... Dental and Craniofacial Research (NIDCR). He remains one of ...
... a national poll aimed at helping with planning efforts ... attack, researchers at the Harvard School of Public Health ... scenario describing a significant anthrax attack in their city ... health recommendations to obtain prophylactic antibiotics. However, a significant ...
... discovery could lead to new treatments, study suggests , FRIDAY, ... treatments for cystic fibrosis, U.S. researchers have identified a defective ... lung disease. , Cystic fibrosis causes thick, sticky mucus to ... one of the most common potentially lethal genetic diseases in ...
... ... ... , , ... ...
Cached Medicine News:Health News:Two Tulsa Pharmacies Penalized for Missing Prescription Drugs 2Health News:Two Tulsa Pharmacies Penalized for Missing Prescription Drugs 3Health News:Second Language Comes Faster When Taught in Own Accent 2Health News:AADR presents honorary membership to Senator Tom Harkin 2Health News:Poll: Hypothetical anthrax attack and antibiotics 2Health News:Poll: Hypothetical anthrax attack and antibiotics 3Health News:Poll: Hypothetical anthrax attack and antibiotics 4Health News:Poll: Hypothetical anthrax attack and antibiotics 5Health News:Poll: Hypothetical anthrax attack and antibiotics 6Health News:Drug Improved Survival in Mice With Cystic Fibrosis 2Health News:Registered Nurses from Public Health - Seattle & King County Hold Informational Picket to Highlight Public Safety Concerns 2Health News:Registered Nurses from Public Health - Seattle & King County Hold Informational Picket to Highlight Public Safety Concerns 3
... microscopes utilize the infinity-corrected optical ... operability in cell checking. The ... microscope suited to routine applications ... tissue culture and embryology to ...
... from the ground-up with ergonomic concerns in ... most adjustable observation tube on the market. ... user can adjust the microscope to suit ... the operator maintain an upright, comfortable posture, ...
... A standard laboratory microscope whose ... imagery combine to make it ... E400 is designed to fit ... the user to fit the ...
... through the enclosed polaroid glasses, these ... screening devise for near point stereopsis ... stereo perception, the images appear to ... The test includes circle patterns for ...
Medicine Products: